|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
Tim Van Hauwermeiren
|
|
gptkbp:collaboratedWith
|
gptkb:Leo_Pharma
gptkb:AbbVie
gptkb:Daiichi_Sankyo
Cilag GmbH International
|
|
gptkbp:country
|
gptkb:Belgium
|
|
gptkbp:developedBy
|
antibody-based therapies
|
|
gptkbp:focusesOn
|
oncology
autoimmune diseases
|
|
gptkbp:foundedBy
|
Hans de Haard
Tim Van Hauwermeiren
Torsten Dreier
|
|
gptkbp:foundedIn
|
2008
|
|
gptkbp:headquartersLocation
|
gptkb:Ghent,_Belgium
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Argenx
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:listedOn
|
gptkb:Euronext_Brussels
gptkb:NASDAQ
|
|
gptkbp:marketCap
|
over $20 billion (as of 2023)
|
|
gptkbp:notableProduct
|
efgartigimod
|
|
gptkbp:numberOfEmployees
|
over 500
|
|
gptkbp:productApprovedFor
|
generalized myasthenia gravis
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:researchApproach
|
SIMPLE Antibody platform
|
|
gptkbp:stockExchange
|
gptkb:Euronext_Brussels
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
ARGX
|
|
gptkbp:therapeuticArea
|
immunology
neurology
hematology
|
|
gptkbp:website
|
https://www.argenx.com/
|
|
gptkbp:bfsParent
|
gptkb:OrbiMed
gptkb:OrbiMed_Advisors
|
|
gptkbp:bfsLayer
|
8
|